Edition:
India

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

0.54USD
2:29am IST
Change (% chg)

$-0.04 (-6.86%)
Prev Close
$0.57
Open
$0.55
Day's High
$0.59
Day's Low
$0.52
Volume
26,581
Avg. Vol
72,765
52-wk High
$4.35
52-wk Low
$0.49

Latest Key Developments (Source: Significant Developments)

Atyr Pharma Appoints Jill Broadfoot As CFO
Tuesday, 31 Jul 2018 

July 31 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA APPOINTS JILL BROADFOOT AS CHIEF FINANCIAL OFFICER.ATYR PHARMA INC - JILL BROADFOOT HAS JOINED ATYR AS CHIEF FINANCIAL OFFICER.  Full Article

Atyr Pharma Inc Posts Qtrly Loss Of $0.36 Per Share
Monday, 14 May 2018 

May 14 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS, PROGRAM PRIORITIZATION AND CORPORATE RESTRUCTURING.CORPORATE RESTRUCTURING INCLUDES AN IMMEDIATE WORKFORCE REDUCTION OF APPROXIMATELY 30% AS WELL AS ADDITIONAL COST SAVING MEASURES.RESTRUCTURING PLAN TO STREAMLINE ITS OPERATIONS AS IT FOCUSES ITS DEVELOPMENT EFFORTS ON FURTHER CLINICAL ADVANCEMENT OF ATYR1923.ATYR PHARMA - NOT TO PROCEED WITH IND-ENABLING ACTIVITIES, INCLUDING GMP MANUFACTURING, FOR PANEL OF ANTIBODIES IDENTIFIED IN ORCA PROGRAM.QTRLY LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.  Full Article

Atyr Pharma Says On Dec 22, Co Entered Into Amendment To Loan And Security Agreement Dated As Of Nov 18, 2016
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Atyr Pharma Inc ::ATYR PHARMA SAYS ON DEC 22, CO ENTERED INTO AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED AS OF NOV 18, 2016 - SEC FILING.ATYR PHARMA - AMENDMENT NOW REQUIRES FOR DRAW OF THIRD TRANCHE OF LOAN TO INCLUDE AUSTRALIA AS QUALIFYING GEOGRAPHY FOR INITIATION OF IMOD.FC TRIAL.  Full Article

aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - aTyr Pharma Inc ::aTyr Pharma announces third quarter 2017 operating results and provides corporate update.aTyr Pharma Inc - ‍expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into middle of 2019​.aTyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.43​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma says ‍John Mendlein transitions from CEO to non-executive board member​
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces leadership transition.Atyr Pharma Inc - ‍John Mendlein transitions from CEO to non-executive board member​.Atyr Pharma Inc - ‍Sanjay Shukla appointed president and CEO​.  Full Article

Atyr Pharma announces promising top-line results from Resolaris
Monday, 24 Apr 2017 

April 24 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy.Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset facioscapulohumeral muscular dystrophy.Atyr believes observed safety results of Resolaris to date are supportive of further advancement of resolaris.  Full Article

aTyr Pharma reports signals of clinical activity in genetically distinct Myopathies with Resolaris in exploratory trials
Tuesday, 13 Dec 2016 

aTyr Pharma Inc - : Top-Line results from a completed phase 1b/2 trial for adult patients with limb-girdle muscular dystrophy 2b . Says resolaris continues to demonstrate a generally well tolerated safety profile in all trials .Reports promising signals of clinical activity in multiple rare genetically distinct myopathies with resolaris™ in exploratory trials.  Full Article